Rapid Health Technology Assessment of Conventional Therapy Combined with Total Glucosides of Paeonia Lactiflora in the Treatment of Oral Lichen Planus

SHEN Xiaoyun; WANG Qian; JIN Jianqiu; LU Zhiyue; ZHANG Bihua

doi:10.14009/j.issn.1672-2124.2022.06.022

您当前的位置：

首页 >

文章列表页 >

Rapid Health Technology Assessment of Conventional Therapy Combined with Total Glucosides of Paeonia Lactiflora in the Treatment of Oral Lichen Planus

更新时间：2022-10-08

- Rapid Health Technology Assessment of Conventional Therapy Combined with Total Glucosides of Paeonia Lactiflora in the Treatment of Oral Lichen Planus
- Vol. 22, Issue 6, Pages: 735-737(2022)
- 作者机构：
  
  1. 无锡口腔医院牙周黏膜科
  2. 北京医院口腔科
  3. 北京医院药学部国家老年医学中心中国医学科学院老年医学研究院
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2022.06.022
  CLC： R781.5
- Published：2022，
扫描看全文
SHEN Xiaoyun, WANG Qian, JIN Jianqiu, et al. Rapid Health Technology Assessment of Conventional Therapy Combined with Total Glucosides of Paeonia Lactiflora in the Treatment of Oral Lichen Planus. [J]. 22(6):735-737(2022)
DOI：

SHEN Xiaoyun, WANG Qian, JIN Jianqiu, et al. Rapid Health Technology Assessment of Conventional Therapy Combined with Total Glucosides of Paeonia Lactiflora in the Treatment of Oral Lichen Planus. [J]. 22(6):735-737(2022) DOI： 10.14009/j.issn.1672-2124.2022.06.022.

摘要

目的：综合评估白芍总苷胶囊治疗口腔扁平苔藓的有效性、安全性和经济性，以期为临床用药提供相关循证依据。方法：通过检索万方数据库、中国知网、中国生物医学文献数据库、Embase、the Cochrane Library和PubMed等数据库，以及卫生技术评估(HTA)官方网站，纳入白芍总苷胶囊的HTA报告、Meta分析/系统评价和药物经济学研究等文献资料，检索时限为建库至2021年11月30日，使用定性描述的方法对纳入的研究进行分析汇总，并利用相关量表对文献及其方法学进行质量评价。结果：共纳入3篇文献，均为白芍总苷胶囊治疗口腔扁平苔藓的相关Meta分析/系统评价，HTA报告和药物经济学研究文献均未检索到。结果显示，在西药常规治疗的基础上联合白芍总苷胶囊治疗口腔扁平苔藓，其临床有效率普遍优于西药常规治疗，并在缓解疼痛症状，改善充血糜烂症状和白纹消退程度，改善外周血T淋巴细胞亚群CD3、CD4、CD8及CD4/CD8水平，降低复发率等方面具有一定的优势；同时，其不良反应发生率低，症状轻微，安全性较好。结论：在常规治疗的基础上联合应用白芍总苷胶囊治疗口腔扁平苔藓具有较好的安全性和有效性。可考虑补充白芍总苷胶囊治疗口腔扁平苔藓的经济学评价证据，对该药开展进一步的药物经济学研究。

Abstract

OBJECTIVE: To comprehensively evaluate the efficacy

safety and economy of total glucosides of Paeoniae paeoniae capsules in the treatment of oral lichen planus

so as to provide relevant evidence-based evidence for clinical use. METHODS: Wanfang Data

CNKI

CBM

Embase

the Cochrane Library and PubMed

and the health technology assessment（HTA） official website were retrieved to collect the HTA report

Meta-analysis/systematic evaluation and pharmacoeconomic studies of total glucosides of Paeoniae paeoniae capsules. The retrieval time was from the establishment of the database to Nov. 30 th

2021.The qualitative description method was used to analyze and summarize the included literature

and the quality of literature and its methodology was evaluated by using relevant scales. RESULTS: A total of 3 articles were included

all of which were related Meta-analysis/systematic evaluation of total glucosides of Paeoniae paeoniae capsules in the treatment of oral lichen planus

yet neither HTA report nor pharmacoeconomics studies was retrieved. On the basis of conventional western medicine treatment

combined with total glucosides of Paeoniae paeoniae capsules in the treatment of oral lichen planus

the clinical efficacy was generally better than that of western medicine conventional treatment

which had certain advantages in relieving painful symptoms

improving the symptoms of congestion and erosion and the degree of leukoplakia regression

improving the levels of CD3

CD4

CD8 and CD4/CD8 of peripheral blood T lymphocyte subsets

and reducing the recurrence rate

etc. Meanwhile

the incidence of adverse drug reactions was low

the symptoms were mild

and the safety was good. CONCLUSIONS: On the basis of conventional treatment

combined with total glucosides of Paeoniae paeoniae capsules in the treatment of oral lichen planus has higher safety and efficacy. Further pharmacoeconomic studies on the drugs may be considered to supplement the evidence from the economic evaluation of Paeoniae paeoniae capsules in the treatment of oral lichen planus.

关键词

口腔扁平苔藓白芍总苷胶囊快速卫生技术评估

Keywords

Oral lichen planusTotal glucosides of Paeoniae paeoniae capsulesRapid health technology assessment

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Rapid Health Technology Assessment of Shuxuening Injection in the Adjuvant Treatment of Ischemic Stroke

Rapid Health Technology Assessment of Roxadustat in the Treatment of Renal Anemia

Rapid Health Technology Assessment of Butylphthalide in the Treatment of Ischemic Cerebro-vascular Disease

Rapid Health Technology Assessment of Xingnaojing Injection in the Treatment of Stroke

Rapid Health Technology Assessment of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor for the Prevention of Chemotherapy-Induced Febrile Neutropenia

Related Author

杨莉萍

陈福安

邵晖

张碧华

LIU Xianjun

PANG Jingyao

SUN Wenfang

LIU Yang

Related Institution

Audit Section, Beijing Xuanwu Traditional Chinese Medicine Hospital

Beijing Hospital

Dept. of Pharmacy, Beijing Luhe Hospital, Capital Medical University

北京市宣武中医医院医疗保险办公室

Dept.of Neurology,Beijing Hospital/National Center for Gerontology/Institute of Geriatric Medicine, Chinese Academy of Medical Sciences/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application

⁰